Source comparison
Muscle Growth, Recovery, and IGF-1 Response Comparison
Muscle protein synthesis (MPS) responds to IGF-1 through two primary pathways: mTOR activation (mechanistic target of rapamycin) and inhibition of myostatin signalling. Both CJC-1295 and HGH elevate IGF-1, but the kinetics differ. CJC-1295 produces pulsatile I
This comparison does not assign a generated winner or score.
- Muscle protein synthesis (MPS) responds to IGF-1 through two primary pathways: mTOR activation (mechanistic target of rapamycin) and inhibition of myostatin signalling. Both CJC-1295 and HGH elevate IGF-1, but the kinetics differ. CJC-1295 produces pulsatile IGF-1 spikes. Serum IGF-1 rises 30–50% above baseline during GH pulse windows, then returns to baseline between pulses. HGH therapy creates sustained IGF-1 elevation (60–120% above baseline, dose-dependent) that doesn't fluctuate.
- Does sustained elevation build more muscle? The evidence is mixed. A 2017 meta-analysis in Sports Medicine reviewing GH administration in non-deficient adults found modest lean mass increases (1.5–2.5 kg over 8–12 weeks at 2–4 IU daily) but minimal strength gains. Suggesting fluid retention and connective tissue growth rather than contractile protein accretion. Peptide secretagogue studies (including CJC-1295 combined with a GHRP like ipamorelin) show IGF-1 increases of 20–40% and lean mass changes of 0.8–1.8 kg over similar timeframes. Smaller magnitude but with preserved endogenous GH pulsatility.
- Recovery capacity improves with both protocols but through slightly different mechanisms. Pulsatile GH (via CJC-1295) enhances overnight tissue repair during deep sleep when natural GH secretion peaks. This aligns with the body's anabolic window. Continuous GH elevation (HGH therapy) provides round-the-clock IGF-1 availability but may reduce sleep quality in some individuals due to hyperglycaemic effects from GH's insulin-antagonist properties. Our team has observed that individuals using CJC-1295 report better subjective sleep quality than those on high-dose HGH, though objective polysomnography data in this population remains limited.